The world faces a staggering selection of threats to health and well-being, with access to healthcare being one of the most pressing social challenges. Every year millions of people in developing countries die from curable infectious diseases because they do not have access to basic healthcare services, including essential medicines. Millions more are unnecessarily exposed to the threat of ill health through inadequate or ineffective disease prevention strategies.
Access to medicines is a complex and multifaceted problem with no simple solutions, with a number of factors preventing equitable access. Over the last decade, the pharmaceutical industry has contributed to addressing healthcare challenges in the developing world by researching new medicines and making them more readily available and affordable. However, despite this, the scale of the healthcare demand means that the industry must now take a more proactive approach.
Christophe Weber will outline the pharmaceutical industryâ€™s response to the global health crisis, both unilaterally and collectively, as well as the barriers and incentives to change. In particular, Mr. Weber will provide the rationale for GlaxoSmithKlineâ€™s recent decision to adopt a bold new approach to access to medicines that includes action on patents, research and development, pricing and innovative partnerships.
Click here for more info.
Christophe Weber, Senior Vice President & Regional Director, GlaxoSmithKline Asia Pacific
- Friday, 15 January 2010
- 5.00 p.m. - 6.30 p.m.
Suntec Singapore International
Convention and Exhibition Centre
Meeting Room 309, Level 3